StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.38 | $0.38 | +1.41% | 89.4M |
| 05-12 | $0.33 | $0.32 | -4.35% | 3.6M |
| 05-13 | $0.30 | $0.29 | -3.71% | 2.0M |
| 05-14 | $0.27 | $0.28 | +2.67% | 1.7M |
| 05-15 | $0.28 | $0.28 | +1.27% | 0.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $961.00K | $5.07M | $3.18M | $2.69M |
Operating Income | $-3.56M | $-10.24M | $-7.46M | $-3.72M |
Net Income | $-3.56M | $-10.18M | $-7.41M | $-3.68M |
EPS (Diluted) | $-0.52 | $-3.98 | $-3.42 | $-2.04 |
Total Assets | $2.17M | $7.45M | $3.18M | $5.57M |
Total Liabilities | $2.84M | $4.57M | $2.30M | $2.51M |
Cash & Equivalents | $745.48K | $4.31M | $1.67M | $2.21M |
Free Cash Flow OCF − CapEx | Not available | $-7.93M | $-6.40M | Not available |
Shares Outstanding | 9.28M | 4.57M | 3.18M | 2.39M |
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.